Illinois Considers Legislation for Prescription Drug Affordability
Illinois is currently evaluating legislative measures to tackle the challenges posed by high prescription drug prices. Proposed bills, HB 1443 and SB 66, aim to establish a Prescription Drug Affordability Board (PDAB) that would scrutinize drug costs and set payment limits to manage expenses effectively. This initiative draws inspiration from the federal Medicare Drug Price Negotiation Program, intending to implement Medicare-negotiated prices as the ceiling for statewide payment limits.
In the pharmaceutical sector, companies often resist efforts to curb drug costs, arguing that lower prices could hinder investments in research and development. However, pricing is typically based on market tolerance rather than development costs, as companies leverage monopoly protections to achieve substantial profits.
Financial analysis reveals that from 2022 to 2025, 15 publicly traded companies involved in the initial rounds of Medicare negotiations spent $4.4 billion more on stock repurchases and dividends than on new pharmaceutical development. This trend highlights that shareholder payouts often match or exceed research investments, with some top-selling drugs in Illinois significantly impacting state health plan expenditures during fiscal years 2024 and 2025.
In 2025, leading pharmaceutical companies allocated $84 billion to shareholder compensation and reported profits of $131 billion, compared to $109 billion spent on research initiatives. When comparing shareholder payouts, companies part of the Medicare price negotiation program exhibited almost three times higher payouts to investors than other S&P 500 firms.
New medicines often benefit from taxpayer-funded research supporting early-stage efforts. Drugs included in Medicare negotiations were developed with foundational research valued at approximately $12 billion in NIH funding, showcasing significant public investment in drug development.
Globally, pharmaceutical companies sell medications at lower prices compared to the U.S., sustaining profitability. The Medicare negotiation framework demonstrates that significant price reductions are possible without compromising revenues, offering a model for states like Illinois. The state's proposed PDAB legislation can extend savings beyond the Medicare population and address affordability challenges for a broader range of drugs.
The notion that price reductions could stifle innovation is contested by evidence suggesting that controlling prices does not necessarily impede the introduction of new drugs. Projections from federal negotiations suggest minimal impact on drug innovation, while anticipated savings for consumers and taxpayers are substantial. Illinois is encouraged to enact legislation that ensures drug pricing does not overshadow the healthcare needs of its residents.